Dashboard
Manage Tickers

SRPT


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

unveiling-26-analyst-insights-on-sarepta-therapeutics
Unveiling 26 Analyst Insights On Sarepta T...
09/06/2024 17:01:44

rbc-capital-reiterates-outperform-on-sarepta-therapeutics-maintains-181-price-target
RBC Capital Reiterates Outperform on Sarep...
09/06/2024 12:47:54

RBC Capital analyst Brian Abrahams reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and maintains $181 price ...

muscle-disease-drug-developer-dyne-therapeutics-stock-plunges-after-updated-data-from-duchenne-muscular-dystrophy
Muscle Disease Drug Developer Dyne Therape...
09/03/2024 16:37:01

Dyne Therapeutics revealed new clinical data from its Phase 1/2 DELIVER trial of DYNE-251 for Duchenne muscular dystrophy, show...

how-is-the-market-feeling-about-sarepta-therapeutics
How Is The Market Feeling About Sarepta Th...
08/16/2024 16:15:18

a-closer-look-at-28-analyst-recommendations-for-sarepta-therapeutics
A Closer Look at 28 Analyst Recommendation...
08/15/2024 16:00:36

rbc-capital-reiterates-outperform-on-sarepta-therapeutics-maintains-181-price-target
RBC Capital Reiterates Outperform on Sarep...
08/15/2024 14:35:27

RBC Capital analyst Brian Abrahams reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and maintains $181 price ...

100-invested-in-this-stock-10-years-ago-would-be-worth-600-today
$100 Invested In This Stock 10 Years Ago W...
08/12/2024 14:30:21

warner-bros-airbnb-and-monster-beverage-are-among-top-10-large-cap-losers-last-week-aug-4-aug-10-are-the-others-in-your-portfolio
Warner Bros, Airbnb And Monster Beverage A...
08/11/2024 15:53:29

These 10 stocks had the biggest drop last week, with McKesson Corporation, BIO-TECHNE Corp, and Warner Bros. Discovery, Inc. be...

rbc-capital-maintains-outperform-on-sarepta-therapeutics-lowers-price-target-to-181
RBC Capital Maintains Outperform on Sarept...
08/08/2024 20:11:55

RBC Capital analyst Brian Abrahams maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and lowers the price targe...

smart-money-is-betting-big-in-srpt-options
Smart Money Is Betting Big In SRPT Options
08/08/2024 19:31:18

citigroup-maintains-neutral-on-sarepta-therapeutics-lowers-price-target-to-160
Citigroup Maintains Neutral on Sarepta The...
08/08/2024 19:06:45

Citigroup analyst David Hoang maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Neutral and lowers the price target from $...

cantor-fitzgerald-maintains-neutral-on-sarepta-therapeutics-lowers-price-target-to-152
Cantor Fitzgerald Maintains Neutral on Sar...
08/08/2024 14:50:19

Cantor Fitzgerald analyst Kristen Kluska maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Neutral and lowers the price ta...

evercore-isi-group-upgrades-sarepta-therapeutics-to-outperform-lowers-price-target-to-179
Evercore ISI Group Upgrades Sarepta Therap...
08/08/2024 13:22:28

Evercore ISI Group analyst Gavin Clark-Gartner upgrades Sarepta Therapeutics (NASDAQ:SRPT) from In-Line to Outperform and lo...

barclays-maintains-overweight-on-sarepta-therapeutics-lowers-price-target-to-203
Barclays Maintains Overweight on Sarepta T...
08/08/2024 12:25:34

Barclays analyst Gena Wang maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Overweight and lowers the price target from $...

mckesson-reports-weak-sales-joins-jfrog-fastly-warner-bros-discovery-and-other-big-stocks-moving-lower-in-thursdays-pre-market-session
McKesson Reports Weak Sales, Joins JFrog, ...
08/08/2024 12:20:45

piper-sandler-maintains-overweight-on-sarepta-therapeutics-lowers-price-target-to-200
Piper Sandler Maintains Overweight on Sare...
08/08/2024 11:27:39

Piper Sandler analyst Biren Amin maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Overweight and lowers the price target ...

sarepta-therapeutics-sees-fy25-net-product-revenue-29b-31b-vs-324b-estimate
Sarepta Therapeutics Sees FY25 Net Product...
08/07/2024 20:37:42

sarepta-therapeutics-q2-2024-adj-eps-044-beats-001-estimate-sales-362931m-miss-391406m-estimate
Sarepta Therapeutics Q2 2024 Adj. EPS $0.4...
08/07/2024 20:09:44

Sarepta Therapeutics (NASDAQ:SRPT) reported quarterly earnings of $0.44 per share which beat the analyst consensus estimate of ...

26-analysts-have-this-to-say-about-sarepta-therapeutics
26 Analysts Have This To Say About Sarepta...
07/29/2024 15:00:22

rbc-capital-upgrades-sarepta-therapeutics-to-outperform-announces-182-price-target
RBC Capital Upgrades Sarepta Therapeutics ...
07/29/2024 10:40:40

RBC Capital analyst Brian Abrahams upgrades Sarepta Therapeutics (NASDAQ:SRPT) from Sector Perform to Outperform and announc...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION